Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: A single centre experience of 45 consecutive patients

International Journal of Surgery

Volumn 12, Issue 12, 2014, Pages 1403-1408

  Saxena, Akshat ^a,b   Meteling, Baerbel ^a   Kapoor, Jada ^b   Golani, Sanjeev ^b   Danta, Mark ^a   Morris, David L ^b   Bester, Lourens ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

Author keywords

HCC; Hepatocellular carcinoma; Morbidity; Radioembolization; Survival; Yttrium 90

Indexed keywords

BILIRUBIN; YTTRIUM 90; YTTRIUM;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ELECTROCORTICOGRAPHY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MALE; NAUSEA; OVERALL SURVIVAL; PLEURA EFFUSION; PROSPECTIVE STUDY; RADIOEMBOLIZATION; RADIOISOTOPE THERAPY; VOMITING; ADVERSE EFFECTS; ANALYSIS OF VARIANCE; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BRACHYTHERAPY; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84918842159     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2014.07.269     Document Type: Article

References (30)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61(2):69-90.
2. Altekruse S.F., McGlynn K.A., Reichman M.E. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J.Clin. Oncol. 2009, 27(9):1485-1491.
3. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J.Hepatol. 2012, 56(4):908-943.
4. Llovet J.M., Bustamante J., Castells A., Vilana R., Ayuso Mdel C., Sala M., et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 1999, 29(1):62-67.
5. Soubrane O., Goumard C., Laurent A., Tranchart H., Truant S., Gayet B., et al. Laparoscopic Resection of Hepatocellular Carcinoma: a French Survey in 351 Patients 2013 Jul 24, HPB, Oxford.
6. Mazzaferro V., Llovet J.M., Miceli R., Bhoori S., Schiavo M., Mariani L., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009, 10(1):35-43.
7. Forner A., Llovet J.M., Bruix J. Hepatocellular carcinoma. Lancet 2012 Mar 31, 379(9822):1245-1255.
8. Lo C.M., Ngan H., Tso W.K., Liu C.L., Lam C.M., Poon R.T., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35(5):1164-1171.
9. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
10. Llovet J.M., Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003, 37(2):429-442.
11. Acomparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. N.Engl. J. Med. 1995 May 11, 332(19):1256-1261.
12. Moreno-Luna L.E., Yang J.D., Sanchez W., Paz-Fumagalli R., Harnois D.M., Mettler T.A., et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc. Interv. Radiol. 2013, 36(3):714-723.
13. Salem R., Lewandowski R.J., Mulcahy M.F., Riaz A., Ryu R.K., Ibrahim S., et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010, 138(1):52-64.
14. Hilgard P., Hamami M., Fouly A.E., Scherag A., Muller S., Ertle J., et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010, 52(5):1741-1749.
15. Salem R., Lewandowski R.J., Kulik L., Wang E., Riaz A., Ryu R.K., et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011, 140(2):497-507. e2.
16. Carr B.I., Kondragunta V., Buch S.C., Branch R.A. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010 Mar 1, 116(5):1305-1314.
17. Lance C., McLennan G., Obuchowski N., Cheah G., Levitin A., Sands M., et al. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J.Vasc. Interv. Radiol. 2011, 22(12):1697-1705.
18. Bester L., Salem R. Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization. J.Vasc. Interv. Radiol. 2007, 18(10):1310-1314.
19. Salem R., Thurston K.G. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J.Vasc. Interv. Radiol. 2006, 17(8):1251-1278.
20. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J.Natl. Cancer Inst. 2000 Feb 2, 92(3):205-216.
21. Mazzaferro V., Sposito C., Bhoori S., Romito R., Chiesa C., Morosi C., et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology 2013, 57(5):1826-1837.
22. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N.Engl. J. Med. 2008 Jul 24, 359(4):378-390.
23. Memon K., Kulik L., Lewandowski R.J., Wang E., Riaz A., Ryu R.K., et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011, 141(2):526-535. 35 e1-2.
24. Virmani S., Rhee T.K., Ryu R.K., Sato K.T., Lewandowski R.J., Mulcahy M.F., et al. Comparison of hypoxia-inducible factor-1 alpha expression before and after transcatheter arterial embolization in rabbit VX2 liver tumors. J.Vasc. Interv. Radiol. 2008, 19(10):1483-1489.
25. Leelawat K., Laisupasin P., Kiatdilokrut A., Pongtongpool T., Narong S., Samkhumphim N., et al. The effect of doxorubicin on the changes of serum vascular endothelial growth factor (VEGF) in patients with hepatocellular carcinoma after transcatheter arterial chemoembolization (TACE). J.Med. Assoc. Thai. 2008, 91(10):1539-1543.
26. Sato K., Lewandowski R.J., Bui J.T., Omary R., Hunter R.D., Kulik L., et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere): assessment of hepatic arterial embolization. Cardiovasc. Interv. Radiol. 2006, 29(4):522-529.
27. Salem R., Gilbertsen M., Butt Z., Memon K., Vouche M., Hickey R., et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin. Gastroenterol. Hepatol. Oct 2013, 11(10):1358-1365.
28. Lewandowski R.J., Kulik L.M., Riaz A., Senthilnathan S., Mulcahy M.F., Ryu R.K., et al. Acomparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am. J. Transpl. 2009, 9(8):1920-1928.
29. Inarrairaegui M., Pardo F., Bilbao J.I., Rotellar F., Benito A., D'Avola D., et al. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma. Eur. J. Surg. Oncol. 2012, 38(7):594-601.
30. Naymagon S., Warner R.R., Patel K., Harpaz N., Machac J., Weintraub J.L., et al. Gastroduodenal ulceration associated with radioembolization for the treatment of hepatic tumors: an institutional experience and review of the literature. Dig. Dis. Sci. 2010, 55(9):2450-2458.